First in Korea to Administer Lutetium-177 PSMA Therapy in 2020
200 Sessions for 84 Patients

The Urology Cancer Center at Seoul St. Mary’s Hospital Cancer Hospital has achieved a cumulative total of 200 radioligand therapy sessions for patients with metastatic prostate cancer.


Seoul St. Mary’s Hospital announced on August 31 that, after administering the nation’s first lutetium-177 (Lu-177) prostate-specific membrane antigen (PSMA) targeted radionuclide therapy on November 2, 2020, it has performed a total of 200 treatments for 84 patients with metastatic prostate cancer as of July 21.


The medical staff of the Urologic Cancer Center at Seoul St. Mary's Hospital are taking a commemorative photo celebrating the accumulation of 200 cases of radionuclide ligand therapy for metastatic prostate cancer after a regular multidisciplinary conference. From the front row, right side: Seong-Hoo Hong, Department of Urology; Youngjin Choi, Department of Pathology; Lee Ji-yeol, Hospital Director; Yushin Ha, Department of Urology; Juhyun Oh, Department of Nuclear Medicine, Professors. Seoul St. Mary's Hospital

The medical staff of the Urologic Cancer Center at Seoul St. Mary's Hospital are taking a commemorative photo celebrating the accumulation of 200 cases of radionuclide ligand therapy for metastatic prostate cancer after a regular multidisciplinary conference. From the front row, right side: Seong-Hoo Hong, Department of Urology; Youngjin Choi, Department of Pathology; Lee Ji-yeol, Hospital Director; Yushin Ha, Department of Urology; Juhyun Oh, Department of Nuclear Medicine, Professors. Seoul St. Mary's Hospital

View original image

Lu-177 PSMA radioligand therapy is a treatment method applied to metastatic castration-resistant prostate cancer. The therapy targets PSMA, which is highly expressed in prostate cancer cells, and delivers the radionuclide Lu-177 to treat the cancer. Before treatment, imaging examinations are conducted to assess the PSMA expression of the tumor and the extent of metastasis, determining the patient’s suitability for therapy. For suitable patients, a radiopharmaceutical containing Lu-177 is administered intravenously. The drug binds to PSMA-expressing cancer cells, and beta radiation emitted by Lu-177 damages the DNA of nearby cancer cells.


Seoul St. Mary’s Hospital is not only using approved therapies but is also participating in clinical trials of PSMA-targeted theranostics drugs being developed by domestic and international pharmaceutical companies. Theranostics is an approach that combines diagnosis and treatment using the same molecular target.


The Urology Cancer Center operates a multidisciplinary consultation system involving the departments of urology, oncology, radiation oncology, radiology, pathology, and nuclear medicine. The team reviews a patient’s pathology and radiological findings, disease progression, and previous treatment history to collaboratively discuss the treatment strategy and sequence, including nuclear medicine therapies.


Professor Juhyun Oh from the Department of Nuclear Medicine stated, “Reaching 200 cases signifies that Seoul St. Mary’s Hospital has the experience and capability to cover the entire process of prostate cancer theranostics. We will continue to listen to our patients and provide personalized care through multidisciplinary consultations.” Yushin Ha, professor of urology and director of the Urology Cancer Center, said, “Treatment options for metastatic castration-resistant prostate cancer remain limited, so being able to evaluate nuclear medicine therapies alongside surgery, medication, and radiation treatment in multidisciplinary meetings is meaningful in expanding options for our patients.”



Hospital Director Lee Jiyeol said, “By collaborating with specialized domestic radiopharmaceutical companies, we have established in-house facilities for the production of diagnostic radiopharmaceuticals. Building on this infrastructure, which connects imaging diagnoses to the formulation of treatment plans, we will expand our participation in theranostics clinical trials.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing